Kamada Ltd Stock News

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...

KMDA remains a buy as it delivers strong earnings growth, robust cash generation, and trades at a discount to healthcare peers with an attractive FCF yield. Q2 results confirm ongoing operating leverage, with each $1 in new sales producing $3-$5 in incremental operating profit and EBITDA margins above industry averages. Strategic growth pillars—organic expansion and infrastructure investment, i...

Kamada Ltd. (NASDAQ:KMDA ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Eva Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division James Philip Sidoti - Sidoti & Company, LLC Brian Ritchie - Lifesci Advisors, LLC Operator Greetings, ...

REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd.

REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that, while circumstances in the Middle East are evolving, the Company is continuing the operations an...

Start Time: 08:30 January 1, 0000 8:53 AM ET Kamada Ltd. (NASDAQ:KMDA ) Q1 2025 Earnings Conference Call May 14, 2025, 08:30 AM ET Company Participants Amir London - CEO Chaime Orlev - CFO Brian Ritchie - LifeSci Advisors Conference Call Participants Annabel Samimy - Stifel James Sidoti - Sidoti & Company Operator Greetings, and welcome to the Kamada First Quarter 2025 Earnings Conference Call.

REHOVOT, Israel and HOBOKEN, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months ended March 31, 2025.